REMD Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.remdbio.com
Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- REMD Biotherapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06272695
- Locations
- 🇺🇸
Altman Clinical and Translational Research Institute, San Deigo, California, United States
🇺🇸Diablo Clinical Research, Walnut Creek, California, United States
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Type1 Diabetes Mellitus
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- REMD Biotherapeutics, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT03117998
- Locations
- 🇺🇸
AMCR Institute, Escondido, California, United States
🇺🇸Marin Endocrine Care & Research, Greenbrae, California, United States
🇺🇸Altman Clinical and Translational Research Institute, San Diego, California, United States
Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Type 1 Diabetes MellitusDiabetes
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- REMD Biotherapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT02715193
Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- DiabetesType 2 Diabetes Mellitus
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- REMD Biotherapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT02455011
News
No news found